Biobot Analytics
Biobot Analytics develops a wastewater intelligence platform that converts sewage measurements into predictive public-health signals.
Biobot Analytics develops a wastewater intelligence platform that converts sewage measurements into predictive public-health signals.
Biobot converts wastewater measurements into predictive, privacy-preserving community-level signals that identify disease and substance-use trends before they appear in hospital or official reporting. No individual, household, or address is identifiable in the data it publishes.
Its installed base includes nationwide programs contracted with HHS and the White House Office of National Drug Control Policy, giving it sampling breadth and government relationships that later entrants must build. NIH SBIR Phase I, II, and III awards and TIME recognition provide external validation of the method.
Source: biobot.io
Wastewater surveillance sits at the intersection of public health, biosecurity, and pharmaceutical intelligence, where demand is shifting toward earlier population-level signals for infectious disease and substance use. Government programs have made sewage monitoring a standing part of U.S. public-health infrastructure.
Biobot is extending beyond public-health customers toward private-sector markets such as pharma forecasting and clinical-trial support, as covered in its 2025 expansion profile. Federal engagements with HHS and ONDCP anchor a national data position in that market.
Source: cambridgeday.com
Biobot sells through a demo-led enterprise and government process rather than public self-serve pricing. Prospective buyers request demonstrations and are routed through dedicated programs for federal, state and local, and pharma and life-science customers.
Cambridge Day reported municipal pricing in its 2025 profile of the company's expansion. Subscription contracts are negotiated per jurisdiction, sewershed coverage, and selected analyte panels.
Source: biobot.io
Biobot's wastewater intelligence platform combines municipal wastewater sampling with proprietary analytics and machine learning to report pathogen and substance trends at community level. Panels cover respiratory viruses, gastrointestinal and arboviral pathogens, opioids, stimulants, and treatment medications, and the company states more than 50 human-health trends are tracked.
Delivery surfaces include interactive dashboards, map visualizations, weekly ZIP- and county-level data, CSV downloads, and API integrations. Biobot Advance packages the data layer for pharmaceutical and life-science buyers, and public risk reports extend selected findings to a general audience.
Source:
